New Weekly Tracker to Follow Oral GLP-1 Prescription Race
Fierce Pharma launches a weekly data-driven tracker to monitor how Novo Nordisk's Wegovy pill and Eli Lilly's Foundayo compete for the oral weight-loss market.
Fierce Pharma has introduced a weekly Oral GLP-1 Tracker, a new data feature built on analyst notes and IQVIA prescription data. The aim is to provide ongoing visibility into how oral weight-loss drugs are performing in the market.
The tracker will focus on prescription trends and market share shifts as Novo Nordisk's Wegovy pill and Eli Lilly's Foundayo compete to become the leading oral GLP-1 option. Both companies are vying for a large patient population seeking convenient weight-loss treatments.
In its first edition, the tracker notes that the holiday period took a toll on prescriptions. No specific figures were provided in the announcement, but the seasonal dip sets a baseline for the weekly series.
More in Medicine & Biotech
Ebola Vaccine Trial Launches in DR Congo Outbreak Zone
Health workers in DR Congo have begun testing whether a vaccine designed for a different Ebola strain can protect against the current outbreak.
Beacon Gene Therapy for Rare Vision Loss Succeeds in Pivotal Trial
A pivotal trial of Beacon Therapeutics' gene therapy for X-linked retinitis pigmentosa improved visual acuity, clearing the path toward an FDA submission.
Alkermes orexin agonist shows early promise for ADHD
Early-stage data suggest Alkermes' orexin agonist could expand the drug class beyond sleep disorders into ADHD.
Telix to Buy ITM for $1.65B, Challenging Novartis in Radiopharma
The acquisition gives Telix a late-stage pipeline and supply network that could compete with Novartis' Lutathera.